First-in-Human, Phase 1 Study of AMT-253, an Anti-MUC18 Antibody- Drug Conjugate, in Patients with Advanced Solid Tumors

  • Haydon, Andrew (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date6/12/23 → 8/12/25

Keywords

  • clinical trial
  • solid tumour
  • oncology